These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 23075293

  • 1. Solid nanocrystalline dispersions of ziprasidone with enhanced bioavailability in the fasted state.
    Thombre AG, Caldwell WB, Friesen DT, McCray SB, Sutton SC.
    Mol Pharm; 2012 Dec 03; 9(12):3526-34. PubMed ID: 23075293
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations.
    Thombre AG, Shah JC, Sagawa K, Caldwell WB.
    Int J Pharm; 2012 May 30; 428(1-2):8-17. PubMed ID: 22349051
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Preparation and evaluation of ziprasidone-phospholipid complex from sustained-release pellet formulation with enhanced bioavailability and no food effect.
    Miao Y, Chen G, Ren L, Ouyang P.
    J Pharm Pharmacol; 2016 Feb 30; 68(2):185-94. PubMed ID: 26748446
    [Abstract] [Full Text] [Related]

  • 6. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
    Dening TJ, Rao S, Thomas N, Prestidge CA.
    Eur J Pharm Biopharm; 2016 Apr 30; 101():33-42. PubMed ID: 26812284
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.
    Lincoln J, Stewart ME, Preskorn SH.
    J Psychiatr Pract; 2010 Mar 30; 16(2):103-14. PubMed ID: 20511734
    [Abstract] [Full Text] [Related]

  • 9. Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.
    McNamara D, Yin S, Pan D, Crull G, Timmins P, Vig B.
    Mol Pharm; 2017 Feb 06; 14(2):377-385. PubMed ID: 28068097
    [Abstract] [Full Text] [Related]

  • 10. Effect of cyclodextrin derivation and amorphous state of complex on accelerated degradation of ziprasidone.
    Hong J, Shah JC, Mcgonagle MD.
    J Pharm Sci; 2011 Jul 06; 100(7):2703-16. PubMed ID: 21283987
    [Abstract] [Full Text] [Related]

  • 11. Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone.
    Thombre AG, Shamblin SL, Malhotra BK, Connor AL, Wilding IR, Caldwell WB.
    J Control Release; 2015 Sep 10; 213():10-17. PubMed ID: 26130417
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effect of food on the absorption of oral ziprasidone.
    Miceli JJ, Glue P, Alderman J, Wilner K.
    Psychopharmacol Bull; 2007 Sep 10; 40(3):58-68. PubMed ID: 18007569
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect.
    Thombre AG, Herbig SM, Alderman JA.
    Pharm Res; 2011 Dec 10; 28(12):3159-70. PubMed ID: 21674263
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.